Lyophilized Injectable Drugs Market Size By Drug (Anti-infective, Anti-neoplastic, Anticoagulant, Hormones, Antiarrhythmic), By Indication (Autoimmune Diseases, Respiratory Diseases, Gastrointestinal Disorders, Oncology, Cardiovascular Diseases, Infectiou

Lyophilized Injectable Drugs Market Size By Drug (Anti-infective, Anti-neoplastic, Anticoagulant, Hormones, Antiarrhythmic), By Indication (Autoimmune Diseases, Respiratory Diseases, Gastrointestinal Disorders, Oncology, Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders), By Delivery (Prefilled Diluent Syringes, Multi-step Devices), By Packaging (Vials, Cartridges, Prefilled Devices), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 - 2030

The global lyophilized injectable drugs market is poised to record substantial growth over the forecast timeframe 2022-2030. Extensive development in healthcare infrastructure over the last decade has fostered the integration of advanced technologies and the development of novel drugs. The emergence of new pandemics and epidemics have further accelerated the need for drug discovery and research & development investments.

Leading healthcare and pharma companies are boosting efforts to develop novel drug delivery systems. Meanwhile consolidated initiatives from manufacturers making medical devices to provide best-in-class, cost-effective, and easy-to-operate tools will favor further expansion of the market in emerging economies. In May 2022, Pfizer unveiled a global drug development center in Chennai, India. The advanced capabilities of the new facility include both active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) of a wide range of complex formulations. It will also include lyophilized injections, device-combination products, and ready-to-use formulations.

The lyophilized injectable drugs market share is segregated into drug, indication, delivery, packaging, distribution channel, and region. By drug, the industry is fragmented into anti-neoplastic, anticoagulant, antiarrhythmic, anti-infective, hormones, and others. In 2021, the anticoagulant segment held over 3.5% share of the lyophilized injectable drugs market.

Anticoagulants are mainly used to treat blood clots in severe cases such as in coronary artery disease (CAD) patients with a higher risk of a heart attack. The rising prevalence of chronic diseases across the globe due to high levels of stress, obesity, and unhealthy lifestyle choices will propel the demand for lyophilized injectable anticoagulant drugs.

In terms of indication, the overall market landscape is bifurcated into oncology, gastrointestinal disorders, autoimmune diseases, cardiovascular diseases, metabolic disorders, infectious diseases, respiratory diseases, and others. Among these, the industry value from gastrointestinal disorders segment is estimated to reach over USD 5 billion in 2021. Growing incidences of gastrointestinal disorders among the elderly, as high as 35%, showcase significant prospects for pharmaceutical companies.

With regard to the packaging, the market is divided into cartridges, vials, and prefilled devices. The market share from vials segment is projected to witness over 12.5% CAGR between 2022-2030, on account of several packaging benefits offered by the product. Vials are widely available and ensure a longer shelf life of the product. This type of packaging is ideal for single as well as multiple doses with a volume capacity ranging from 0.1 to 200 ml. Additionally, vials are compatible with any drug formulation as the structure is rather simple consisting of a glass body and a stopper.

Based on the distribution channel, in 2021, the hospital pharmacy segment held over 54% share of the lyophilized injectable drugs market. High preference for hospital pharmacies can be credited to better interaction between healthcare professionals, prescribers, and patients. These setups are easily accessible and provide a wide variety of medications including specialized and advanced drugs.

Latin America lyophilized injectable drugs market size is projected to expand at over 11.5% CAGR from 2022 to 2030. Increasing awareness among the population regarding the benefits of medications will complement industry growth across the region. Countries in LATAM have a massive landscape of pharmaceutical business with a surging number of online drug stores and offline pharmacies.